Literature DB >> 9502186

In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes.

S Cianfarani1, B Tedeschi, D Germani, S P Prete, P Rossi, P Vernole, D Caporossi, B Boscherini.   

Abstract

BACKGROUND: We have reported previously that growth hormone (GH) therapy increases cell radiosensitivity; in this study we tested whether GH itself or IGFs induce chromosome aberrations and investigated the expression of p53 protein in response to DNA damage.
METHODS: Human peripheral blood lymphocytes were incubated with GH [100 and 1000 microg L(-1)], insulin-like growth factor I [IGF-I; 150 and 1000 microg L(-1)] and IGF-II [600 and 1200 microg L(-1)] for 24 h. The radiomimetic agent bleomycin [BLM; 5 microgm L(-1)] was added in the last 3 h. Cytogenetic analysis was performed by assessing the percentages of damaged cells (%DC) and chromosome aberrations (%CA). The expression of p53 was investigated by flow cytometric assay using the monoclonal antibody DO-7, and expressed as percentage positive cells and mean fluorescence intensity.
RESULTS: BLM significantly increased both percentage DC and percentage CA and p53 expression (P < 0.01). The %DC was unaffected by the tested peptides. IGF-I [150 microg L(-1)] increased spontaneous percentage CA (P < 0.01). All peptides further increased the BLM-induced chromosome breakage: GH 100 and 1000 microg L(-1) by 30% and 73% respectively, IGF-I 150 and 1000 microg L(-1) by 41% and 96% respectively and IGF-II 600 and 1200 microg L(-1) by 89% and 45% respectively. The spontaneous and BLM-induced expression of p53 was unaffected by GH, whereas it was significantly increased by IGFs (P < 0001).
CONCLUSIONS: These results indicate that the DNA-damaging effect of BLM is amplified by GH and, more markedly, IGF-I and -II. IGF-I and -II also stimulate p53 protein expression that, taking part in DNA repair, may counteract the IGF action on genome stability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502186     DOI: 10.1046/j.1365-2362.1998.00247.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 2.  Peptide Hormone Regulation of DNA Damage Responses.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

Review 3.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

4.  Can GH induce chromosome breaks or microsatellite instability in GH-deficient children?

Authors:  C Olivieri; C Danesino; S Scappaticci; M Bozzola
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

Review 5.  How do cytokines trigger genomic instability?

Authors:  Ioannis L Aivaliotis; Ioannis S Pateras; Marilena Papaioannou; Christina Glytsou; Konstantinos Kontzoglou; Elizabeth O Johnson; Vassilis Zoumpourlis
Journal:  J Biomed Biotechnol       Date:  2012-06-17

Review 6.  Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis.

Authors:  Polyxeni Kalisperati; Evangelia Spanou; Ioannis S Pateras; Penelope Korkolopoulou; Anastasia Varvarigou; Ioannis Karavokyros; Vassilis G Gorgoulis; Panayiotis G Vlachoyiannopoulos; Stavros Sougioultzis
Journal:  Front Genet       Date:  2017-02-27       Impact factor: 4.599

Review 7.  Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.

Authors:  Haim Werner; Rive Sarfstein; Karthik Nagaraj; Zvi Laron
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

Review 8.  Karyotype Aberrations in Action: The Evolution of Cancer Genomes and the Tumor Microenvironment.

Authors:  Nicolaas C Baudoin; Mathew Bloomfield
Journal:  Genes (Basel)       Date:  2021-04-12       Impact factor: 4.096

Review 9.  Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance.

Authors:  Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.